Literature DB >> 15880389

Benefits and costs of methadone treatment: results from a lifetime simulation model.

Gary A Zarkin1, Laura J Dunlap, Katherine A Hicks, Daniel Mamo.   

Abstract

Several studies have examined the benefits and costs of drug treatment; however, they have typically focused on the benefits and costs of a single treatment episode. Although beneficial for certain analyses, the results are limited because they implicitly treat drug abuse as an acute problem that can be treated in one episode. We developed a Monte Carlo simulation model that incorporates the chronic nature of drug abuse. Our model represents the progression of individuals from the general population aged 18-60 with respect to their heroin use, treatment for heroin use, criminal behavior, employment, and health care use. We also present three model scenarios representing an increase in the probability of going to treatment, an increase in the treatment length of stay, and a scenario in which drug treatment is not available to evaluate how changes in treatment parameters affect model results. We find that the benefit-cost ratio of treatment from our lifetime model (37.72) exceeds the benefit-cost ratio from a static model (4.86). The model provides a rich characterization of the dynamics of heroin use and captures the notion of heroin use as a chronic recurring condition. Similar models can be developed for other chronic diseases, such as diabetes, mental illness, or cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880389     DOI: 10.1002/hec.999

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  30 in total

1.  Needed: Longitudinal Research That Can Inform Dynamic Models for the Treatment of Addiction as a Disease.

Authors:  Thomas F Hilton; Redonna K Chandler; Wilson M Compton
Journal:  Eval Rev       Date:  2008-02

Review 2.  Conducting economic evaluations of screening and brief intervention for hazardous drinking: Methods and evidence to date for informing policy.

Authors:  Alexander J Cowell; Jeremy W Bray; Michael J Mills; Jesse M Hinde
Journal:  Drug Alcohol Rev       Date:  2010-11

3.  Individual and system influences on waiting time for substance abuse treatment.

Authors:  Carey J A Carr; Jiangmin Xu; Cristina Redko; D Timothy Lane; Richard C Rapp; John Goris; Robert G Carlson
Journal:  J Subst Abuse Treat       Date:  2007-05-23

Review 4.  Medical profiteering: the economics of methadone dispensation.

Authors:  Bohdan Nosyk; Aslam H Anis
Journal:  CMAJ       Date:  2009-05-26       Impact factor: 8.262

Review 5.  Opioid Use Disorder in Pregnancy: Health Policy and Practice in the Midst of an Epidemic.

Authors:  Elizabeth E Krans; Stephen W Patrick
Journal:  Obstet Gynecol       Date:  2016-07       Impact factor: 7.661

6.  Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors:  Marta O Soares; Luísa Canto E Castro
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

7.  Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study.

Authors:  Bohdan Nosyk; M Douglas Anglin; Mary-Lynn Brecht; Viviane Dias Lima; Yih-Ing Hser
Journal:  Am J Epidemiol       Date:  2013-02-27       Impact factor: 4.897

8.  The causal effect of opioid substitution treatment on HAART medication refill adherence.

Authors:  Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

9.  Treating drug abuse and addiction in the criminal justice system: improving public health and safety.

Authors:  Redonna K Chandler; Bennett W Fletcher; Nora D Volkow
Journal:  JAMA       Date:  2009-01-14       Impact factor: 56.272

10.  Evidence-based drug policy: it starts with good evidence and ends with policy reform.

Authors:  B Nosyk; E Wood
Journal:  Int J Drug Policy       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.